LY-2828360

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameLY-2828360
Drug Alias NameLY 2828360
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB2 receptor agonists
TargetsCannabinoid CB2 receptor
Therapy Area/IndicationsOsteoarthritis, Knee
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsOsteoarthritis, Knee

Other Information

ATC CodeN/A
Related LinksN/A